CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 33 enrolled
Drug / intervention
Erwinasedrug
Likely dose
Erwinase 20,000 Unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00506597
NCT00506597N/ACompleted
CompareCT.gov

Erwinia L-Asparaginase (Erwinase) Study in Patients With Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center·interventional·Posted Jul 25, 2007·Updated Sep 11, 2014

In Brief

A clinical study evaluating Erwinase for Leukemia. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to allow doctors to use Erwinia L-Asparaginase (Erwinase®) as a replacement for patients who are allergic to E.coli L-asparaginase or Pegylated E.coli L-asparaginase as part of the treatment for acute lymphoblastic leukemia (ALL) or T or B cell lymphoma. This trial was part of a multi institutional effort by the drug company to make Erwinase available for use.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 25, 2007
Enrollment StartMay 1, 2007
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 18.9 years ago

Interventions

Erwinasedrug

If allergic to E.Coli Asparaginase = 1 Dose (20,000 Units/m\^2) Daily; If allergic to Pegylated Asparaginase = 6 Doses (25,000 Units/m\^2) Daily Every Other Day. Received as an injection through a needle in vein, under the skin, or in muscle.